The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder: A Double-Blind Randomized Placebo-Controlled Trial
Abstract
OBJECTIVE: Despite the staggering consequences of the opioid epidemic, limited nonopioid medication options have been developed to treat this medical and public health crisis. This study investigated the potential of cannabidiol (CBD), a nonintoxicating phytocannabinoid, to reduce cue-induced craving and anxiety, two critical features of addiction that often contribute to relapse and continued drug use, in drug-abstinent individuals with heroin use disorder. METHODS: This exploratory double-blind randomized placebo-controlled trial assessed the acute (1 hour, 2 hours, and 24 hours), short-term (3 consecutive days), and protracted (7 days after the last of three consecutive daily administrations) effects of CBD administration (400 or 800 mg, once daily for 3 consecutive days) on drug cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder. Secondary measures assessed participants' positive and negative affect, cognition, and physiological status. RESULTS: Acute CBD administration, in contrast to placebo, significantly reduced both craving and anxiety induced by the presentation of salient drug cues compared with neutral cues. CBD also showed significant protracted effects on these measures 7 days after the final short-term (3-day) CBD exposure. In addition, CBD reduced the drug cue-induced physiological measures of heart rate and salivary cortisol levels. There were no significant effects on cognition, and there were no serious adverse effects. CONCLUSIONS: CBD's potential to reduce cue-induced craving and anxiety provides a strong basis for further investigation of this phytocannabinoid as a treatment option for opioid use disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Bergamaschi, M. M., Queiroz, R. H. C., Chagas, M. H. N., de Oliveira, D. C. G., De Martinis, B. S., Kapczinski, F., Quevedo, J., Roesler, R., Schröder, N., Nardi, A. E., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.6 · Cited by 771 · cited 2×
“In addition, CBD has been shown to reduce anxiety (20, 21), which we expected to be enhanced by the presentation of drug cues (22).”
National and state treatment need and capacity for opioid agonist medication-assisted treatment
Jones, C. M., Campopiano, M., Baldwin, G., & McCance-Katz, E. (2015) · American Journal of Public Health · doi:10.2105/ajph.2015.302664 · Cited by 668
Iffland, K., & Grotenhermen, F. (2017) · Cannabis & Cannabinoid Research · doi:10.1089/can.2016.0034 · Cited by 645
Safety and side effects of cannabidiol, a Cannabis sativa constituent
Machado Bergamaschi, M., Helena Costa Queiroz, R., Waldo Zuardi, A., & Alexandre S. Crippa, J. (2011) · Current Drug Safety · doi:10.2174/157488611798280924 · Cited by 558 · cited 1×
“Consistent with previous reports (27, 28), no serious adverse events were noted in association with CBD administration throughout the duration of the trial.”
Crippa, J. A. S., Derenusson, G. N., Ferrari, T. B., Wichert-Ana, L., Duran, F. L., Martin-Santos, R., Simões, M. V., Bhattacharyya, S., Fusar-Poli, P., Atakan, Z., et al. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110379283 · Cited by 535
Taylor, L., Gidal, B., Blakey, G., Tayo, B., & Morrison, G. (2018) · CNS Drugs · doi:10.1007/s40263-018-0578-5 · Cited by 471
Fusar-Poli, P., Crippa, J. A., Bhattacharyya, S., Borgwardt, S. J., Allen, P., Martin-Santos, R., Seal, M., Surguladze, S. A., O’Carrol, C., Atakan, Z., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2008.519 · Cited by 465
Antianxiety effect of cannabidiol in the elevated plus-maze
Guimarães, F. S., Chiaretti, T. M., Graeff, F. G., & Zuardi, A. W. (1990) · Psychopharmacology · doi:10.1007/bf02244012 · Cited by 379 · cited 1×
“The results of numerous animal models have also reinforced the anxiolytic role of CBD (34, 35).”
Effects of ipsapirone and cannabidiol on human experimental anxiety
Zuardi, A. W., Cosme, R. A., Graeff, F. G., & Guimarães, F. S. (1993) · Journal of Psychopharmacology · doi:10.1177/026988119300700112 · Cited by 364
Treatment utilization among persons with opioid use disorder in the United States
Wu, L.-T., Zhu, H., & Swartz, M. S. (2016) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.10.015 · Cited by 340
Effects of cannabidiol (CBD) on regional cerebral blood flow
Crippa, J. A. D. S., Zuardi, A. W., Garrido, G. E. J., Wichert-Ana, L., Guarnieri, R., Ferrari, L., Azevedo-Marques, P. M., Hallak, J. E. C., McGuire, P. K., & Busatto, G. F. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300340 · Cited by 307
Attentional bias predicts heroin relapse following treatment
Marissen, M. A. E., Franken, I. H. A., Waters, A. J., Blanken, P., Van Den Brink, W., & Hendriks, V. M. (2006) · Addiction · doi:10.1111/j.1360-0443.2006.01498.x · Cited by 280
Ren, Y., Whittard, J., Higuera-Matas, A., Morris, C. V., & Hurd, Y. L. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4291-09.2009 · Cited by 210
Self-citationFogaça, M. V., Campos, A. C., Coelho, L. D., Duman, R. S., & Guimarães, F. S. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.03.001 · Cited by 207
Bhattacharyya, S. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.161 · Cited by 203
Morgan, C. J., Freeman, T. P., Schafer, G. L., & Curran, H. V. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.58 · Cited by 196 · cited 1×
“CBD has been shown in clinical (23, 30) and pre-clinical (15, 29) studies to be most sensitive to cue stimuli, which, together with the results from the present study, suggests that CBD may be relevant to the attentional saliency of drug cues that are associated with craving contributing to relapse…”
González‐Cuevas, G., Martin‐Fardon, R., Kerr, T. M., Stouffer, D. G., Parsons, L. H., Hammell, D. C., Banks, S. L., Stinchcomb, A. L., & Weiss, F. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0050-8 · Cited by 178
Parker, L. A., Burton, P., Sorge, R. E., Yakiwchuk, C., & Mechoulam, R. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1825-7 · Cited by 171
Cannabidiol reduces ethanol consumption, motivation and relapse in mice
Viudez‐Martínez, A., García‐Gutiérrez, M. S., Navarrón, C. M., Morales‐Calero, M. I., Navarrete, F., Torres‐Suárez, A. I., & Manzanares, J. (2017) · Addiction Biology · doi:10.1111/adb.12495 · Cited by 169
Hurd, Y. L., Yoon, M., Manini, A. F., Hernandez, S., Olmedo, R., Ostman, M., & Jutras-Aswad, D. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0373-7 · Cited by 167
Self-citationUpdate on Barriers to Pharmacotherapy for Opioid Use Disorders
Sharma, A., Kelly, S. M., Mitchell, S. G., Gryczynski, J., O’Grady, K. E., & Schwartz, R. P. (2017) · Current Psychiatry Reports · doi:10.1007/s11920-017-0783-9 · Cited by 163
Role of cues and contexts on drug‐seeking behaviour
Perry, C. J., Zbukvic, I., Kim, J. H., & Lawrence, A. J. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12735 · Cited by 151
Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers
Babalonis, S. L., Haney, M., Malcolm, R. J., Lofwall, M. R., Votaw, V. R., Sparenborg, S., & WALSH, S. L. (2016) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.11.030 · Cited by 143
Manini, A. F., Yiannoulos, G., Bergamaschi, M. M., Hernandez, S. H., Olmedo, R., Barnes, A. J., Winkel, G. H., Sinha, R., Jutras‐Aswad, D., Huestis, M. A., et al. (2015) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000118 · Cited by 139
Self-citationMerrick, J., Lane, B., Sebree, T. B., Yaksh, T. L., O'Neill, C. S., & Banks, S. L. (2016) · Cannabis and Cannabinoid Research · doi:10.1089/can.2015.0004 · Cited by 139
Stress and drug-cue-induced craving in opioid-dependent individuals in naltrexone treatment
Hyman, S. M., Fox, H., Hong, K.-I. A., Doebrick, C., & Sinha, R. (2007) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.15.2.134 · Cited by 133
Schmidt, A., Borgwardt, S., Gerber, H., Wiesbeck, G. A., Schmid, O., Riecher‐Rössler, A., Smieskova, R., Lang, U. E., & Walter, M. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.10.019 · Cited by 129
Hindocha, C., Freeman, T. P., Grabski, M., Stroud, J., Crudgington, H., Davies, A. C., Das, R., Lawn, W., Morgan, C. J. A., & Curran, H. V. (2018) · Addiction · doi:10.1111/add.14243 · Cited by 111
Fatseas, M., Denis, C., Massida, Z., Verger, M., Franques-Rénéric, P., & Auriacombe, M. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.05.015 · Cited by 94 · cited 1×
“This was examined with the presentation of drug-associated environmental cues to induce craving and stress responsivity in these individuals because such stimuli are strong triggers for opioid use (13, 18, 19).”
Fatseas, M., Serre, F., Swendsen, J., & Auriacombe, M. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.03.008 · Cited by 89
Lake, S., Walsh, Z., Kerr, T. H., Cooper, Z. D., Buxton, J. A., Wood, E., Ware, M. A., & Milloy, M. (2019) · PLoS Medicine · doi:10.1371/journal.pmed.1002967 · Cited by 89
Preston, K. L., Kowalczyk, W. J., Phillips, K. A., Jobes, M. L., Vahabzadeh, M., Lin, J.-L., Mezghanni, M., & Epstein, D. H. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4966-9 · Cited by 77
A Conversion of oral cannabidiol to delta9-tetrahydrocannabinol seems not to occur in humans
Nahler, G., Grotenhermen, F., Zuardi, A. W., & Crippa, J. A. S. (2017) · Cannabis & Cannabinoid Research · doi:10.1089/can.2017.0009 · Cited by 61
Glial neuroimmune signaling in opioid reward
Zhang, H., Largent‐Milnes, T. M., & Vanderah, T. W. (2019) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2019.11.012 · Cited by 50
Lake, S., Nosova, E., Buxton, J. A., Walsh, Z., Socias, M. E., Hayashi, K., Kerr, T. H., & Milloy, M. (2020) · PLoS ONE · doi:10.1371/journal.pone.0233463 · Cited by 44
Cue-induced craving to paraphernalia and drug images in opioid dependence: Opioid Cue Craving
McHugh, R. K., Fulciniti, F., Mashhoon, Y., & Weiss, R. D. (2016) · The American Journal on Addictions · doi:10.1111/ajad.12344 · Cited by 39
Hindocha, C., Freeman, T. P., Grabski, M., Crudgington, H., Davies, A. C., Stroud, J., Das, R. K., Lawn, W., Morgan, C. J. A., & Curran, H. V. (2018) · Scientific Reports · doi:10.1038/s41598-018-25846-2 · Cited by 38
Priming primary care providers to engage in evidence-based discussions about cannabis with patients
Kansagara, D. L., Becker, W. C., Ayers, C. K., & Tetrault, J. M. (2019) · Addiction Science & Clinical Practice · doi:10.1186/s13722-019-0171-3 · Cited by 24
Evidence shows that cannabis has fewer relative harms than opioids
Lake, S., Socias, M. E., & Milloy, M. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.74120 · Cited by 18
Use and misuse of opioid agonists in opioid addiction
Modesto‐Lowe, V., Swiezbin, K., Chaplin, M., & Hoefer, G. (2017) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.84a.16091 · Cited by 17
Research works printed but not linked: 1
- 10.1097/ADM.0000000000000412 · doi:10.1097/adm.0000000000000412
Cited by
Freeman, T. P., Craft, S., Wilson, J., Stylianou, S., ElSohly, M., Di Forti, M., & Lynskey, M. T. (2021) · Addiction · doi:10.1111/add.15253 · Cited by 337
Cannabidiol: pharmacology and therapeutic targets
Britch, S. C., Babalonis, S., & Walsh, S. L. (2021) · Psychopharmacology · doi:10.1007/s00213-020-05712-8 · Cited by 307
García-Gutiérrez, M. S., Navarrete, F., Gasparyan, A., Austrich-Olivares, A., Sala, F., & Manzanares, J. (2020) · Biomolecules · doi:10.3390/biom10111575 · Cited by 306
Rupasinghe, H. P. V., Davis, A., Kumar, S. K., Murray, B., & Zheljazkov, V. D. (2020) · Molecules · doi:10.3390/molecules25184078 · Cited by 260
Cannabinoids, the endocannabinoid system, and pain: a review of preclinical studies
Finn, D. P., Haroutounian, S., Hohmann, A. G., Krane, E., Soliman, N., & Rice, A. S. C. (2021) · Pain · doi:10.1097/j.pain.0000000000002268 · Cited by 254
Metadata
- Authors
- Hurd, Y. L., Spriggs, S., Alishayev, J., Winkel, G., Gurgov, K., Kudrich, C., Oprescu, A. M., & Salsitz, E.
- Venue
- American Journal of Psychiatry
- Published
- 2019-11-01
- Volume
- 176
- Issue
- 11
- Pages
- 911-922
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2946027664
- Cited by
- 343
- References
- 41
- FWCI
- 24.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.